Haiyan Tu

9PUBLICATIONS
46CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer diagnosisCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Nov 28, 2025
Cellular dynamics in cerebrospinal fluid unveils the key regulators of intracranial response to immune checkpoint inhibitors in NSCLC brain metastases.

Yang-Si Li, Wenpu Lai, Kai Yin

|Mar 03, 2025
HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study.

John V Heymach, Frans Opdam, Minal Barve

|Jan 24, 2025
Follow-up Analysis Enhances Understanding of Molecular Residual Disease in Localized Non-Small Cell Lung Cancer.

Jia-Tao Zhang, Si-Yang Liu, Xuan Gao

|Apr 20, 2023
Genomic and immune characteristics of HER2-mutated non-small-cell lung cancer and response to immune checkpoint inhibitor-based therapy.

Hai-Yan Tu, Kai Yin, Xiaotian Zhao

|May 11, 2022
Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non-Small Cell Lung Cancer.

Jia-Tao Zhang, Si-Yang Liu, Wei Gao

|Mar 31, 2022
Phase I/Ib dose-escalation study of avelumab in Chinese patients with advanced solid tumors.

Yi-Long Wu, Ying Cheng, Huajun Chen

Pageof 2

Frequent Collaborators

8 joint publications

Yi-Long Wu

4 joint publications

Chongrui Xu

3 joint publications

Qing Zhou

3 joint publications

Si-Yang Maggie Liu